this observational, cross-sectional, national, comparative study, including RMD patients followed in hospital centres of the FAI²R Rare Diseases Healthcare Pathway network and specialist private practitioners caring for patients suffering from inflammatory rheumatism, systemic autoimmune diseases and auto-inflammatory diseases. The objective of the study is to compare RMD patients with COVID 19 infection (cases) to RMD patients who have not had COVID 19 infection (controls) on their mental health.
Inclusion Criteria:
Patient case:
- Patient with inflammatory rheumatism, systemic autoimmune or autoimmune disease
- With confirmed COVID-19 infection (at least one month prior to study inclusion)
- Study information given to the patient
- Patient affiliated to social security
Patient control:
- Patient with inflammatory rheumatism, systemic autoimmune disease or autoimmune
disease.
- Not having had a confirmed COVID-19 infection
- Study information given to the patient
- Patient affiliated to social security
Exclusion Criteria:
- Opposition to participation in the study by the patient and/or his legal
representative
- Adult patient not able to understand the implications and rules of the study
- Protected adults under guardianship or curatorship
Hop Claude Huriez Chu Lille
Lille, France
Eric Hachulla, MD,PhD, Principal Investigator
University Hospital, Lille